ArticleACS medicinal chemistry letters2020
Structural Approach to Assessing the Innovativeness of New Drugs Finds Accelerating Rate of Innovation.
Article in ACS medicinal chemistry letters, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Molecular deep learning at the edge of chemical space.Nature machine intelligence · 2026Article
- Evaluating the Diversity and Target Addressability of DELs using Scaffold Analysis and Machine Learning.ACS medicinal chemistry letters · 2025Article
- Exploring SureChEMBL from a drug discovery perspective.Scientific data · 2024Article
- KinomeMETA: meta-learning enhanced kinome-wide polypharmacology profiling.Briefings in bioinformatics · 2023Article
- Diversifying chemical space of DNA-encoded libraries: synthesis of 2-oxa-1-azaspiro(bicyclo[3.2.0])heptanes on-DNAChemical communications (Cambridge, England) · 2023Article
- Molecular Framework Analysis of the Generated Database GDB-13s.Journal of chemical information and modeling · 2023Article
- The Time and Place for Nature in Drug Discovery.JACS Au · 2022Review
- Rings in Clinical Trials and Drugs: Present and Future.Journal of medicinal chemistry · 2022Review
- Carboranes in drug discovery, chemical biology and molecular imaging.Nature reviews. Chemistry · 2022Review
- Article
- Target-Based Evaluation of "Drug-Like" Properties and Ligand Efficiencies.Journal of medicinal chemistry · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Measuring innovation in the pharmaceutical industry is challenging. Counts of new molecular entities (NMEs) approved by the Food and Drug Administration (FDA) are commonly used, but this measure only gauges quantity not innovativeness. A new indicator of innovation for small molecule and peptide drugs based on structural novelty is proposed and used to analyze recent trends in pharmaceutical innovation. We show pharmaceutical innovation has significantly increased over the last several decades despite recent concerns over an innovation crisis and find Pioneers (a NME whose shape and scaffold were not used in any previously FDA-approved drugs) are significantly more likely to be the source of promising new therapies. Analysis of the underlying source of structural innovation indicates that scaffolds first reported in the CAS REGISTRY five or less years prior to their Investigational New Drug application (IND) or on scaffolds populated with 50 or less other compounds at the time of IND tend to be the main source of Pioneers. Our analysis also shows a widening structural innovation gap between large pharmaceutical companies (Big Pharma) and the rest of the ecosystem even though the number of Big Pharma originated Pioneers has increased.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.